FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2287085364> ?p ?o ?g. }

• W2287085364 endingPage "7578" @default.
• W2287085364 startingPage "7578" @default.
• W2287085364 abstract "7578 Background: To assess the efficacy and safety of bevacizumab-containing regimens in the treatment of advanced, chemotherapy-naive, non-squamous NSCLC on the basis of the two registrative trials (ECOG E4599 trial and BO17704 [AVAiL] trial). Methods: A pooled analysis of the two trials was performed using a random effect model, and the results were summarized as number-needed-to-treat (NNT) and number-needed-to-harm (NNH). The 1-year survival and 6-month progression free rates were assumed as indexes of efficacy, and grade III-IV side effects were assumed as index of safety. Results: One thousand nine hundred twenty two patients were potentially eligible for the pooled analysis, and 1576 patients were included in the final analysis. A large heterogeneity was documented for both 6-month progression free interval (I2 = 88.164%, p = 0.004) and overall survival (I2=73.541, p = 0.052). The absolute risk reduction of 1-year death and 6-month progression were 3.3% (CI-95% = [-6.5]%-13.2%, p = 0.507), with a NNT = 30; and 15.2% (CI-95% = 0.07%-29.6%, p = 0.04), with a NNT = 6 (both in favor of the bevacizumab-containing regimens), respectively. The absolute risk of treatment-related death was 2.4% (CI-95% = 0.8%-3.9%, p = 0.003), with a NNH = 41 against the bevacizumab-containing regimens; that of bleeding was 3.3% (CI-95% = 1.6%-4.9%, p < 0.001), with a NNH = 30; that of hypertension was 6.6% (CI-95% = 4.6%-8.6%, p < 0.001), with a NNH = 15; that of proteinuria was 2.1% (CI-95% = 0.3%-3.8%, p = 0.024), with a NNH = 47; that of neutropenia was 7.3% (CI-95% = 3.2%-11.4%, p < 0.001), with a NNH = 13; that of thrombocytopenia was 1.5% (CI-95% = 0.2%-2.7%, p = 0.021), with a NNH = 66. Conclusions: Adding bevacizumab to standard chemotherapy in the treatment of advanced, chemotherapy-naive, non-squamous NSCLC seems to favor a modest improvement in the main outcomes, with a significant worsening of the safety profile. These data suggest caution in the generalized use of bevacizumab-containing regimens in the treatment of advanced, chemotherapy-naive, non-squamous NSCLC. No significant financial relationships to disclose." @default.
• W2287085364 created "2016-06-24" @default.
• W2287085364 creator A5013086481 @default.
• W2287085364 creator A5020691388 @default.
• W2287085364 creator A5028540747 @default.
• W2287085364 creator A5060683338 @default.
• W2287085364 creator A5081006407 @default.
• W2287085364 creator A5082365619 @default.
• W2287085364 creator A5089852748 @default.
• W2287085364 date "2010-05-20" @default.
• W2287085364 modified "2023-09-27" @default.
• W2287085364 title "Efficacy and safety of bevacizumab in the treatment of advanced, non-squamous non-small cell lung cancer (NSCLC)." @default.
• W2287085364 doi "https://doi.org/10.1200/jco.2010.28.15_suppl.7578" @default.
• W2287085364 hasPublicationYear "2010" @default.
• W2287085364 type Work @default.
• W2287085364 sameAs 2287085364 @default.
• W2287085364 citedByCount "0" @default.
• W2287085364 crossrefType "journal-article" @default.
• W2287085364 hasAuthorship W2287085364A5013086481 @default.
• W2287085364 hasAuthorship W2287085364A5020691388 @default.
• W2287085364 hasAuthorship W2287085364A5028540747 @default.
• W2287085364 hasAuthorship W2287085364A5060683338 @default.
• W2287085364 hasAuthorship W2287085364A5081006407 @default.
• W2287085364 hasAuthorship W2287085364A5082365619 @default.
• W2287085364 hasAuthorship W2287085364A5089852748 @default.
• W2287085364 hasConcept C126322002 @default.
• W2287085364 hasConcept C141071460 @default.
• W2287085364 hasConcept C142454548 @default.
• W2287085364 hasConcept C143998085 @default.
• W2287085364 hasConcept C2776256026 @default.
• W2287085364 hasConcept C2776694085 @default.
• W2287085364 hasConcept C2777802072 @default.
• W2287085364 hasConcept C44249647 @default.
• W2287085364 hasConcept C67774102 @default.
• W2287085364 hasConcept C71924100 @default.
• W2287085364 hasConcept C82789193 @default.
• W2287085364 hasConceptScore W2287085364C126322002 @default.
• W2287085364 hasConceptScore W2287085364C141071460 @default.
• W2287085364 hasConceptScore W2287085364C142454548 @default.
• W2287085364 hasConceptScore W2287085364C143998085 @default.
• W2287085364 hasConceptScore W2287085364C2776256026 @default.
• W2287085364 hasConceptScore W2287085364C2776694085 @default.
• W2287085364 hasConceptScore W2287085364C2777802072 @default.
• W2287085364 hasConceptScore W2287085364C44249647 @default.
• W2287085364 hasConceptScore W2287085364C67774102 @default.
• W2287085364 hasConceptScore W2287085364C71924100 @default.
• W2287085364 hasConceptScore W2287085364C82789193 @default.
• W2287085364 hasIssue "15_suppl" @default.
• W2287085364 hasLocation W22870853641 @default.
• W2287085364 hasOpenAccess W2287085364 @default.
• W2287085364 hasPrimaryLocation W22870853641 @default.
• W2287085364 hasRelatedWork W2012498683 @default.
• W2287085364 hasRelatedWork W2015414840 @default.
• W2287085364 hasRelatedWork W2048128186 @default.
• W2287085364 hasRelatedWork W2107675170 @default.
• W2287085364 hasRelatedWork W2169335753 @default.
• W2287085364 hasRelatedWork W2387455091 @default.
• W2287085364 hasRelatedWork W2473045897 @default.
• W2287085364 hasRelatedWork W2767714585 @default.
• W2287085364 hasRelatedWork W3029430426 @default.
• W2287085364 hasRelatedWork W49755809 @default.
• W2287085364 hasVolume "28" @default.
• W2287085364 isParatext "false" @default.
• W2287085364 isRetracted "false" @default.
• W2287085364 magId "2287085364" @default.
• W2287085364 workType "article" @default.